Global Botulism Illness Market
Global Botulism Illness Market

Botulism Illness Comprehensive Study by Type (Antibiotics, Antitoxins, Other), Application (Hospitals, Clinics, Other), Distribution Channel (OTC, Prescribed) Players and Region - Global Market Outlook to 2024

Botulism Illness Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Jul 2019 Edition 233 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Botulism is a rare but serious fatal paralytic disorder, caused by neurotoxins produced by a bacteria Clostridium botulinum. Rapid advancement in the are of medical technologies and government initiatives supporting research and development in the healthcare industry and the availability of favourable reimbursement policies are the major driving agent in the growth of the very market. In addition, owing to strong efforts by WHO and CDC, the disease is getting irradiated slowly.This growth is primarily driven by Availability of Proper Treatment of Botulism Illness and Huge Spending on R&D Activities and Clean Environment Worldwide.

Major Players, such as Microbiotix (United States), XOMA Corporation (United States), Allergan Inc (Ireland), Pfizer Inc. (United States), Molecular Targeting Technologies (United States), AlphaVax (United States), Morphotek (United States), Azidus (India) and Canbex therapeutics ltd etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • Availability of Proper Treatment of Botulism Illness
  • Huge Spending on R&D Activities and Clean Environment Worldwide

Market Trend

Restraints
  • Lack of Awareness in Some Undeveloped Nations
  • Unavailability of Proper Healthcare Infrastructure

Opportunities
Rising Awareness About the Care and Treatment in Developing Economies
Challenges
High Capital Investments for Treatments and Late Diagnosis of the Disease and Unaffordability in Middle-Income Countries

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Antibiotics
  • Antitoxins
  • Other
By Application
  • Hospitals
  • Clinics
  • Other
By Distribution Channel
  • OTC
  • Prescribed

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Availability of Proper Treatment of Botulism Illness
      • 3.2.2. Huge Spending on R&D Activities and Clean Environment Worldwide
    • 3.3. Market Challenges
      • 3.3.1. High Capital Investments for Treatments and Late Diagnosis of the Disease
      • 3.3.2. Unaffordability in Middle-Income Countries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Botulism Illness, by Type, Application, Distribution Channel and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Botulism Illness (Value)
      • 5.2.1. Global Botulism Illness by: Type (Value)
        • 5.2.1.1. Antibiotics
        • 5.2.1.2. Antitoxins
        • 5.2.1.3. Other
      • 5.2.2. Global Botulism Illness by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Other
      • 5.2.3. Global Botulism Illness by: Distribution Channel (Value)
        • 5.2.3.1. OTC
        • 5.2.3.2. Prescribed
      • 5.2.4. Global Botulism Illness Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Botulism Illness: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Microbiotix (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. XOMA Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan Inc (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Molecular Targeting Technologies (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AlphaVax (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Morphotek (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Azidus (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Canbex therapeutics ltd
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Botulism Illness Sale, by Type, Application, Distribution Channel and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Botulism Illness (Value)
      • 7.2.1. Global Botulism Illness by: Type (Value)
        • 7.2.1.1. Antibiotics
        • 7.2.1.2. Antitoxins
        • 7.2.1.3. Other
      • 7.2.2. Global Botulism Illness by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Other
      • 7.2.3. Global Botulism Illness by: Distribution Channel (Value)
        • 7.2.3.1. OTC
        • 7.2.3.2. Prescribed
      • 7.2.4. Global Botulism Illness Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Botulism Illness: by Type(USD Million)
  • Table 2. Botulism Illness Antibiotics , by Region USD Million (2013-2018)
  • Table 3. Botulism Illness Antitoxins , by Region USD Million (2013-2018)
  • Table 4. Botulism Illness Other , by Region USD Million (2013-2018)
  • Table 5. Botulism Illness: by Application(USD Million)
  • Table 6. Botulism Illness Hospitals , by Region USD Million (2013-2018)
  • Table 7. Botulism Illness Clinics , by Region USD Million (2013-2018)
  • Table 8. Botulism Illness Other , by Region USD Million (2013-2018)
  • Table 9. Botulism Illness: by Distribution Channel(USD Million)
  • Table 10. Botulism Illness OTC , by Region USD Million (2013-2018)
  • Table 11. Botulism Illness Prescribed , by Region USD Million (2013-2018)
  • Table 12. South America Botulism Illness, by Country USD Million (2013-2018)
  • Table 13. South America Botulism Illness, by Type USD Million (2013-2018)
  • Table 14. South America Botulism Illness, by Application USD Million (2013-2018)
  • Table 15. South America Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 16. Brazil Botulism Illness, by Type USD Million (2013-2018)
  • Table 17. Brazil Botulism Illness, by Application USD Million (2013-2018)
  • Table 18. Brazil Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 19. Argentina Botulism Illness, by Type USD Million (2013-2018)
  • Table 20. Argentina Botulism Illness, by Application USD Million (2013-2018)
  • Table 21. Argentina Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 22. Rest of South America Botulism Illness, by Type USD Million (2013-2018)
  • Table 23. Rest of South America Botulism Illness, by Application USD Million (2013-2018)
  • Table 24. Rest of South America Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 25. Asia Pacific Botulism Illness, by Country USD Million (2013-2018)
  • Table 26. Asia Pacific Botulism Illness, by Type USD Million (2013-2018)
  • Table 27. Asia Pacific Botulism Illness, by Application USD Million (2013-2018)
  • Table 28. Asia Pacific Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 29. China Botulism Illness, by Type USD Million (2013-2018)
  • Table 30. China Botulism Illness, by Application USD Million (2013-2018)
  • Table 31. China Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 32. Japan Botulism Illness, by Type USD Million (2013-2018)
  • Table 33. Japan Botulism Illness, by Application USD Million (2013-2018)
  • Table 34. Japan Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 35. India Botulism Illness, by Type USD Million (2013-2018)
  • Table 36. India Botulism Illness, by Application USD Million (2013-2018)
  • Table 37. India Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 38. South Korea Botulism Illness, by Type USD Million (2013-2018)
  • Table 39. South Korea Botulism Illness, by Application USD Million (2013-2018)
  • Table 40. South Korea Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 41. Taiwan Botulism Illness, by Type USD Million (2013-2018)
  • Table 42. Taiwan Botulism Illness, by Application USD Million (2013-2018)
  • Table 43. Taiwan Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 44. Australia Botulism Illness, by Type USD Million (2013-2018)
  • Table 45. Australia Botulism Illness, by Application USD Million (2013-2018)
  • Table 46. Australia Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 47. Rest of Asia-Pacific Botulism Illness, by Type USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Botulism Illness, by Application USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 50. Europe Botulism Illness, by Country USD Million (2013-2018)
  • Table 51. Europe Botulism Illness, by Type USD Million (2013-2018)
  • Table 52. Europe Botulism Illness, by Application USD Million (2013-2018)
  • Table 53. Europe Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 54. Germany Botulism Illness, by Type USD Million (2013-2018)
  • Table 55. Germany Botulism Illness, by Application USD Million (2013-2018)
  • Table 56. Germany Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 57. France Botulism Illness, by Type USD Million (2013-2018)
  • Table 58. France Botulism Illness, by Application USD Million (2013-2018)
  • Table 59. France Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 60. Italy Botulism Illness, by Type USD Million (2013-2018)
  • Table 61. Italy Botulism Illness, by Application USD Million (2013-2018)
  • Table 62. Italy Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 63. United Kingdom Botulism Illness, by Type USD Million (2013-2018)
  • Table 64. United Kingdom Botulism Illness, by Application USD Million (2013-2018)
  • Table 65. United Kingdom Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 66. Netherlands Botulism Illness, by Type USD Million (2013-2018)
  • Table 67. Netherlands Botulism Illness, by Application USD Million (2013-2018)
  • Table 68. Netherlands Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 69. Rest of Europe Botulism Illness, by Type USD Million (2013-2018)
  • Table 70. Rest of Europe Botulism Illness, by Application USD Million (2013-2018)
  • Table 71. Rest of Europe Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 72. MEA Botulism Illness, by Country USD Million (2013-2018)
  • Table 73. MEA Botulism Illness, by Type USD Million (2013-2018)
  • Table 74. MEA Botulism Illness, by Application USD Million (2013-2018)
  • Table 75. MEA Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 76. Middle East Botulism Illness, by Type USD Million (2013-2018)
  • Table 77. Middle East Botulism Illness, by Application USD Million (2013-2018)
  • Table 78. Middle East Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 79. Africa Botulism Illness, by Type USD Million (2013-2018)
  • Table 80. Africa Botulism Illness, by Application USD Million (2013-2018)
  • Table 81. Africa Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 82. North America Botulism Illness, by Country USD Million (2013-2018)
  • Table 83. North America Botulism Illness, by Type USD Million (2013-2018)
  • Table 84. North America Botulism Illness, by Application USD Million (2013-2018)
  • Table 85. North America Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 86. United States Botulism Illness, by Type USD Million (2013-2018)
  • Table 87. United States Botulism Illness, by Application USD Million (2013-2018)
  • Table 88. United States Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 89. Canada Botulism Illness, by Type USD Million (2013-2018)
  • Table 90. Canada Botulism Illness, by Application USD Million (2013-2018)
  • Table 91. Canada Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 92. Mexico Botulism Illness, by Type USD Million (2013-2018)
  • Table 93. Mexico Botulism Illness, by Application USD Million (2013-2018)
  • Table 94. Mexico Botulism Illness, by Distribution Channel USD Million (2013-2018)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Botulism Illness: by Type(USD Million)
  • Table 105. Botulism Illness Antibiotics , by Region USD Million (2019-2024)
  • Table 106. Botulism Illness Antitoxins , by Region USD Million (2019-2024)
  • Table 107. Botulism Illness Other , by Region USD Million (2019-2024)
  • Table 108. Botulism Illness: by Application(USD Million)
  • Table 109. Botulism Illness Hospitals , by Region USD Million (2019-2024)
  • Table 110. Botulism Illness Clinics , by Region USD Million (2019-2024)
  • Table 111. Botulism Illness Other , by Region USD Million (2019-2024)
  • Table 112. Botulism Illness: by Distribution Channel(USD Million)
  • Table 113. Botulism Illness OTC , by Region USD Million (2019-2024)
  • Table 114. Botulism Illness Prescribed , by Region USD Million (2019-2024)
  • Table 115. South America Botulism Illness, by Country USD Million (2019-2024)
  • Table 116. South America Botulism Illness, by Type USD Million (2019-2024)
  • Table 117. South America Botulism Illness, by Application USD Million (2019-2024)
  • Table 118. South America Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 119. Brazil Botulism Illness, by Type USD Million (2019-2024)
  • Table 120. Brazil Botulism Illness, by Application USD Million (2019-2024)
  • Table 121. Brazil Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 122. Argentina Botulism Illness, by Type USD Million (2019-2024)
  • Table 123. Argentina Botulism Illness, by Application USD Million (2019-2024)
  • Table 124. Argentina Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 125. Rest of South America Botulism Illness, by Type USD Million (2019-2024)
  • Table 126. Rest of South America Botulism Illness, by Application USD Million (2019-2024)
  • Table 127. Rest of South America Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 128. Asia Pacific Botulism Illness, by Country USD Million (2019-2024)
  • Table 129. Asia Pacific Botulism Illness, by Type USD Million (2019-2024)
  • Table 130. Asia Pacific Botulism Illness, by Application USD Million (2019-2024)
  • Table 131. Asia Pacific Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 132. China Botulism Illness, by Type USD Million (2019-2024)
  • Table 133. China Botulism Illness, by Application USD Million (2019-2024)
  • Table 134. China Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 135. Japan Botulism Illness, by Type USD Million (2019-2024)
  • Table 136. Japan Botulism Illness, by Application USD Million (2019-2024)
  • Table 137. Japan Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 138. India Botulism Illness, by Type USD Million (2019-2024)
  • Table 139. India Botulism Illness, by Application USD Million (2019-2024)
  • Table 140. India Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 141. South Korea Botulism Illness, by Type USD Million (2019-2024)
  • Table 142. South Korea Botulism Illness, by Application USD Million (2019-2024)
  • Table 143. South Korea Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 144. Taiwan Botulism Illness, by Type USD Million (2019-2024)
  • Table 145. Taiwan Botulism Illness, by Application USD Million (2019-2024)
  • Table 146. Taiwan Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 147. Australia Botulism Illness, by Type USD Million (2019-2024)
  • Table 148. Australia Botulism Illness, by Application USD Million (2019-2024)
  • Table 149. Australia Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 150. Rest of Asia-Pacific Botulism Illness, by Type USD Million (2019-2024)
  • Table 151. Rest of Asia-Pacific Botulism Illness, by Application USD Million (2019-2024)
  • Table 152. Rest of Asia-Pacific Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 153. Europe Botulism Illness, by Country USD Million (2019-2024)
  • Table 154. Europe Botulism Illness, by Type USD Million (2019-2024)
  • Table 155. Europe Botulism Illness, by Application USD Million (2019-2024)
  • Table 156. Europe Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 157. Germany Botulism Illness, by Type USD Million (2019-2024)
  • Table 158. Germany Botulism Illness, by Application USD Million (2019-2024)
  • Table 159. Germany Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 160. France Botulism Illness, by Type USD Million (2019-2024)
  • Table 161. France Botulism Illness, by Application USD Million (2019-2024)
  • Table 162. France Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 163. Italy Botulism Illness, by Type USD Million (2019-2024)
  • Table 164. Italy Botulism Illness, by Application USD Million (2019-2024)
  • Table 165. Italy Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 166. United Kingdom Botulism Illness, by Type USD Million (2019-2024)
  • Table 167. United Kingdom Botulism Illness, by Application USD Million (2019-2024)
  • Table 168. United Kingdom Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 169. Netherlands Botulism Illness, by Type USD Million (2019-2024)
  • Table 170. Netherlands Botulism Illness, by Application USD Million (2019-2024)
  • Table 171. Netherlands Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 172. Rest of Europe Botulism Illness, by Type USD Million (2019-2024)
  • Table 173. Rest of Europe Botulism Illness, by Application USD Million (2019-2024)
  • Table 174. Rest of Europe Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 175. MEA Botulism Illness, by Country USD Million (2019-2024)
  • Table 176. MEA Botulism Illness, by Type USD Million (2019-2024)
  • Table 177. MEA Botulism Illness, by Application USD Million (2019-2024)
  • Table 178. MEA Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 179. Middle East Botulism Illness, by Type USD Million (2019-2024)
  • Table 180. Middle East Botulism Illness, by Application USD Million (2019-2024)
  • Table 181. Middle East Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 182. Africa Botulism Illness, by Type USD Million (2019-2024)
  • Table 183. Africa Botulism Illness, by Application USD Million (2019-2024)
  • Table 184. Africa Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 185. North America Botulism Illness, by Country USD Million (2019-2024)
  • Table 186. North America Botulism Illness, by Type USD Million (2019-2024)
  • Table 187. North America Botulism Illness, by Application USD Million (2019-2024)
  • Table 188. North America Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 189. United States Botulism Illness, by Type USD Million (2019-2024)
  • Table 190. United States Botulism Illness, by Application USD Million (2019-2024)
  • Table 191. United States Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 192. Canada Botulism Illness, by Type USD Million (2019-2024)
  • Table 193. Canada Botulism Illness, by Application USD Million (2019-2024)
  • Table 194. Canada Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 195. Mexico Botulism Illness, by Type USD Million (2019-2024)
  • Table 196. Mexico Botulism Illness, by Application USD Million (2019-2024)
  • Table 197. Mexico Botulism Illness, by Distribution Channel USD Million (2019-2024)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Botulism Illness: by Type USD Million (2013-2018)
  • Figure 5. Global Botulism Illness: by Application USD Million (2013-2018)
  • Figure 6. Global Botulism Illness: by Distribution Channel USD Million (2013-2018)
  • Figure 7. South America Botulism Illness Share (%), by Country
  • Figure 8. Asia Pacific Botulism Illness Share (%), by Country
  • Figure 9. Europe Botulism Illness Share (%), by Country
  • Figure 10. MEA Botulism Illness Share (%), by Country
  • Figure 11. North America Botulism Illness Share (%), by Country
  • Figure 12. Global Botulism Illness share by Players 2018 (%)
  • Figure 13. Global Botulism Illness share by Players (Top 3) 2018(%)
  • Figure 14. Global Botulism Illness share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Microbiotix (United States) Revenue, Net Income and Gross profit
  • Figure 17. Microbiotix (United States) Revenue: by Geography 2018
  • Figure 18. XOMA Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. XOMA Corporation (United States) Revenue: by Geography 2018
  • Figure 20. Allergan Inc (Ireland) Revenue, Net Income and Gross profit
  • Figure 21. Allergan Inc (Ireland) Revenue: by Geography 2018
  • Figure 22. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer Inc. (United States) Revenue: by Geography 2018
  • Figure 24. Molecular Targeting Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 25. Molecular Targeting Technologies (United States) Revenue: by Geography 2018
  • Figure 26. AlphaVax (United States) Revenue, Net Income and Gross profit
  • Figure 27. AlphaVax (United States) Revenue: by Geography 2018
  • Figure 28. Morphotek (United States) Revenue, Net Income and Gross profit
  • Figure 29. Morphotek (United States) Revenue: by Geography 2018
  • Figure 30. Azidus (India) Revenue, Net Income and Gross profit
  • Figure 31. Azidus (India) Revenue: by Geography 2018
  • Figure 32. Canbex therapeutics ltd Revenue, Net Income and Gross profit
  • Figure 33. Canbex therapeutics ltd Revenue: by Geography 2018
  • Figure 34. Global Botulism Illness: by Type USD Million (2019-2024)
  • Figure 35. Global Botulism Illness: by Application USD Million (2019-2024)
  • Figure 36. Global Botulism Illness: by Distribution Channel USD Million (2019-2024)
  • Figure 37. South America Botulism Illness Share (%), by Country
  • Figure 38. Asia Pacific Botulism Illness Share (%), by Country
  • Figure 39. Europe Botulism Illness Share (%), by Country
  • Figure 40. MEA Botulism Illness Share (%), by Country
  • Figure 41. North America Botulism Illness Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Microbiotix (United States)
  • XOMA Corporation (United States)
  • Allergan Inc (Ireland)
  • Pfizer Inc. (United States)
  • Molecular Targeting Technologies (United States)
  • AlphaVax (United States)
  • Morphotek (United States)
  • Azidus (India)
  • Canbex therapeutics ltd
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation